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CHAPTER 1: INTRODUCTION 
1.1 Introduction to Diabetes and Insulin Signaling Pathway 
 
1.1.1 Introduction to Diabetes 
 Diabetes is a metabolic disorder characterized by hyperglycemia, high blood glucose 
levels. In 2014, 29.1 million people in the United States had diabetes, out of which 21 million 
were diagnosed and 8.1 million were undiagnosed [1]. Prediabetes is a condition in which the 
blood sugar is high but not high enough to be considered diabetic and an estimated 86 million 
people in the U.S has prediabetes [1]. In 2013, diabetes was ranked as the seventh leading cause 
of death in the United States [1]. Other than elevated blood glucose levels, there are many other 
complications associated with diabetes that affect a number of organs/tissues in the body. About 
half of all people with diabetes have some form of diabetic neuropathy, nerve damage caused by 
diabetes [2]. The chances of experiencing a stroke or developing heart disease are higher than 
average for people with diabetes [3]. High levels of blood sugar, over time, can also lead to 
diabetic nephropathy, a kidney disease [4]. Diabetic retinopathy occurs when there is a retina 
disorder caused by diabetes [5]. 
 There are two major classifications of diabetes, type 1 and type 2. Type 1 diabetes 
accounts for about 5% of all diagnosed cases and Type 2 diabetes accounts for about 90% to 
95% of all cases [1]. Type 1 diabetes, commonly known as juvenile diabetes, is when the body 
produces little or no insulin due to the loss of pancreatic beta cells. This type of diabetes is 
usually diagnosed in young adults and children. Type 2 diabetes is caused by relative insulin 
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deficiency and insulin resistance, which is a condition when the body does not use insulin 
properly.  This type of diabetes is usually diagnosed in older adults. 
 Insulin is a hormone produced by the islet cells in the pancreas that regulates a wide 
variety of biological processes like metabolism, growth and cell survival [6]. The majority of 
insulin-stimulated glucose uptake occurs in the skeletal muscle [7]. Insulin resistance in the 
skeletal muscle is one of the major defects in type 2 diabetes [8]. 
 
1.1.2 Insulin Signaling Pathway 
 Insulin increases glucose uptake in the muscle and fat and thus decreases blood sugar 
levels [9]. It also increases the storage of energy reserves in fat, liver, and muscle through the 
stimulation of lipogenesis, glycogen synthesis and protein synthesis [10]. These cellular responses 
are a result of the activation of a number of different pathways that occur in the liver, muscle and 
fat cells. Insulin binds to the insulin receptor (IR), a tyrosine kinase receptor, inducing a 
structural change enabling autophosphorylation of the receptor to take place. Once 
phosphorylated, the receptor phosphorylates various tyrosine residues on docking proteins [e.g., 
insulin receptor substrate 1 (IRS1), Shc and adaptor protein with PH and SH2 domain (APS)] 
[11]. Tyrosine phosphorylation of these substrates initiates the signaling of the phosphoinositide-3 
kinase/Akt (PI 3K) and Ras/MAPK pathways [12]. In the PI 3K pathway, activated Akt/PKB 
increases insulin-stimulated translocation of a glucose transporter (GLUT4) in the muscle and 
adipose tissues [13]. Cell growth-related gene expression is regulated by the MAPK pathway 
through a signaling cascade that is also activated by insulin [14].  
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1.2 Protein Phosphatase 2A (PP2A) Regulation and Effects on 
Insulin 
 Reversible phosphorylation of proteins is a major mechanism that regulates a large 
number of intracellular events (like metabolism, transport and secretion, transcription and 
translation of genes) in eukaryotic cells [15]. Phosphatases carry out dephosphorylation by 
removing a phosphate group from phosphorylated serine, threonine and tyrosine residues, 
leading to activation or deactivation of substrate proteins.  
PP2A is one of the most abundant serine/threonine protein phosphatases, and is 
responsible for regulating the activities of a large number of signal transduction proteins [16]. 
PP2A makes up as much as 1% of total cellular proteins and together with protein phosphatase 1 
(PP1), accounts for >90% of all Ser/Thr phosphatase activities in most tissues and cells [17]. 
PP2A can exist in two different forms: a trimeric form [18] and a dimeric form [19]. The core 
enzyme, dimeric form, consists of a 36kDa catalytic subunit C (PP2AC) and a 65 kDa scaffold 
subunit A (PP2AA), while the trimeric form consists of the core enzyme and a 55kDa regulatory 
subunit B (PP2AB) [20] (Fig 2). There are 4 types of regulatory B subunits: B (B55/PR55), B’ 
(B56/PR61), B’’ (PR48/PR72/PR130) and B’’’ (PR93/PR110), while the A and C subunits exist 
in the α and β isoforms [17-20]. 
 
1.2.1 Regulation of PP2A 
 PP2A is regulated by subunit diversity, post-translational modifications, substrate protein 
interactions and auto-regulation [21]. Due to a large number of potential associations of the A and 
B regulatory subunits, a total of 75 dimeric and trimeric PP2A holoenzymes can be generated 
  
4
[22]. The combination of the A, B and C subunit isoforms affects the activity and specificity of the 
PP2A complex against a particular substrate.  
 Experiments done in vivo and in vitro have shown that phosphorylation of tyrosine307 
inhibited the activity of PP2Ac by preventing its interaction with the regulatory subunit [21-23]. In 
addition, methylation of Leu309 by leucine carboxylmethyltransferase 1 (LCMT1) has been 
shown to enhance the binding affinity of the A and C subunits to distinct regulatory subunits [21, 
22].  
 Various cellular proteins such as I1PP2A and I2PP2A regulate the activity of PP2A by 
directly interacting with the free C subunit or with the AC core dimer [21-24]. Aside from cellular 
proteins, some small compounds found naturally such as okadaic acid can inhibit the enzymatic 
activity of PP2A [25]. 
 
1.2.2 PP2A in Insulin Signaling 
 The effect of insulin on PP2A abundance in the muscle of type 2 diabetic subjects was 
shown by Højlund et al. They showed that upon insulin stimulation in vivo, PP2A levels in 
control subjects were reduced (when compared to basal levels), but not in type 2 diabetic 
subjects [16].  
 Saturated fatty acids like palmitate have been shown to negatively regulate insulin 
signaling by activating PP2A [26-28]. Wu et al. observed a decrease in Thr172 phosphorylation of 
AMPK, a substrate of PP2A, when bovine aortic endothelial cells (BAECs) were incubated with 
palmitate [26]. In rat hepatocytes [27] and human skeletal muscle cells [28], treated with fatty acids, 
PP2A was seen to have been upregulated and Akt phosphorylation and activation was decreased. 
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 PP2A activation was observed in INS-1 832/13, an insulin-secreting pancreatic β-cell line 
[29] and C2C12 skeletal myotubes [30] treated with ceramide. Cazzolli and associates observed a 
reduction in glycogen synthesis through the inhibition of phosphorylation on Akt/PKB upon 
insulin stimulation mediated through activated PP2A [30]. 
 In the context of insulin signaling, PP2A interacts with various proteins involved in the 
signaling cascade (e.g. AKT, GSK3, etc.).  In recent studies, 514 proteins were identified as 
PP2Ac interaction partners in pancreatic β-cells [31]. Of those 514 proteins, 89 proteins showed a 
significant difference in response to glucotoxic treatment [31]. Some of those interaction partners 
have been known to be involved in insulin secretion (Rab5c, RhoA), gluconeogenesis (WDR5) 
and glucose flux control (GFPT1) [31].  
 
1.3 Insulin Sensitivity and Protein-Protein Interactions 
 
1.3.1 Measuring Insulin Sensitivity 
 Insulin sensitivity can be measured directly using hyperinsulinemic euglycemic clamp 
and the insulin suppression test, and can be measured indirectly using minimal model analysis of 
frequently sampled intravenous glucose tolerance test (FSIVGTT) and oral glucose tolerance test 
(OGTT) [32].   
Where the maintenance of steady-state conditions is crucial, the hyperinsulinemic 
euglycemic clamp is considered the “gold standard” for measuring insulin sensitivity because it 
directly measures the effects of insulin in vivo [33].   
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1.3.2 Protein-protein interactions (PPIs) 
Protein-protein complexes are an important component of various biological functions 
such as cell cycle regulation, gene transcription, signal transduction [34], etc. Correct formation of 
these complexes is necessary for normal body function. Abnormality in the formation of these 
complexes can lead to irregular cell signals and ultimately cause diseases. Currently, scientists 
are targeting protein complexes to treat diseases like Huntington’s disease [35]. Studying PPIs can 
help us understand the function of a particular target protein and analyze the signaling pathways.  
PPIs can be classified as homo-oligomeric and hetero-oligomeric based on the type of 
protein units involved; non-obligate and obligate based on the stability of the structure, and 
transient and permanent based on the lifetime of the complex [36].  
These interactions can be detected using biochemical methods (like co-
immunoprecipitation and chemical cross-linking) and biophysical methods (like NMR 
Spectroscopy and X-ray crystallography). The most commonly used high-throughput methods 
are yeast two-hybrid screening and affinity purification coupled to mass spectrometry [37-39]. 
 
1.4 Mass Spectrometry 
 Mass spectrometry is a powerful approach for the identification, characterization and 
quantification of proteins [40]. This is a very sensitive technique that can be used to identify 
compounds as low as 1 part per trillion in chemically complex mixtures and as small as 10-12 g 
for a compound of mass 1000Da [40]. The main components of a mass spectrometer include an 
ion source, a mass analyzer and a detector. 
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1. Ion Source: This device generates charged particles and the two commonly used ion 
sources are Matrix-Assisted Laser Desorption Ionization (MALDI) and Electrospray 
Ionization (ESI) [40]. 
2. Mass Analyzer: This is used to separate ions based on their mass-to-charge ratio. A few 
commonly used mass analyzers include quadrupole, ion trap, orbitrap analyzers, etc. [40]. 
3. Detector: This device is used to record the charge induced when the ion hits a surface (for 
example the electron multiplier) or record the current produced when the ion passes by 
(for example the image current detector) [40].  
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CHAPTER 2: RESEARCH DESIGN AND METHODS 
 Clinical and proteomics data acquisition and data analysis used for this project were 
illustrated in Fig. 3. First, we recruited subjects and performed comprehensive screening tests 
(Visit 1) to ensure patient eligibility. This was then followed by in-patient clinical tests (Visit 2) 
which included the hyperinsulinemic-euglycemic clamp and muscle biopsies. The skeletal 
muscle cells collected were analyzed in the following order: homogenization of the biopsy 
sample; immunoprecipitation of PP2Ac; the eluate were subjected to in-solution trypsin 
digestion, peptide extraction and UPLC-nanoESI-MS/MS analysis to identify co-
immunoprecipitating proteins. Immunoprecipitation of NIgG (non-specific control) was carried 
out to minimize the possibility of obtaining false positive results. 
 
2.1 Materials 
2.1.1 Reagents 
 Reagents were acquired from these suppliers: sequencing-grade modified trypsin 
(Promega, Madison, WI); protein A sepharose, protein G-agarose and iodoacetamide (Sigma, St 
Louis, MO); C18 ziptip (Millipore, Billerica, MA); Normal mouse IgG antibody, anti-PP2A C-
subunit antibody and PP2A Immunoprecipitation phosphatase assay kit (Millipore, Billerica, 
MA). 
 
2.1.2 Subjects 
 A total of 8 volunteers –glucose tolerant lean controls (LC)—were recruited and took part 
in the study at the Clinical Research Center at Wayne State University. The study was explained 
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in detail, including potential risks, to all participants and written consent was obtained before 
participation. None of the participants engaged in heavy exercise, nor did they have any 
significant medical problems. All forms of exercise were stopped at least 2 days before the study. 
The protocol was approved by the Institutional Review Board of Wayne State University. 
 
2.1.3 Hyperinsulinemic-Euglycemic Clamp with muscle biopsies 
 To determine insulin sensitivity and expose the skeletal muscle to insulin in vivo, a 
hyperinsulinemic-euglycemic clamp was used, as previously described [41]. Having the 
participant fast for a minimum of ten hours overnight, the study began around 08:30 hours (time 
-60 mins). One catheter was placed in each arm, one to maintain the infusion of insulin and 
glucose throughout the study; the second was used to collect blood to observe the participants 
blood glucose levels. At 09:00 hours (time -30mins), a biopsy of the vastus lateralis muscle was 
performed. As soon as possible, the biopsy samples were cleaned of blood, connective tissue and 
fat, and then transferred to ice cold PBS for primary cell culture. At 09:30 hours (time 0 mins), a 
second muscle biopsy was taken and then continuous human insulin (Humulin R; Eli Lilly, 
Indianapolis, IN) infusion began and continued for 120 mins. The plasma glucose was measured 
every five 5 minutes throughout the clamp. Throughout the insulin infusion, euglycemia was 
maintained at ∼90 mg/dl. At 11:30 hours (time 120), the third muscle biopsy was taken and the 
insulin infusion was shut off.  
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2.2 Sample Preparation and Analysis 
2.2.1 Sample Preparation 
 Cultured cells from the skeletal muscle biopsies were generated from the 8 human muscle 
biopsies, and myoblasts were differentiated into myotubes in normal or hyperinsulinemic 
hyperglycemic condition; Each condition was stimulated with or without insulin for 15 minutes 
before harvesting the cells (cells were treated with the HGHI media to induce insulin resistance 
[41-43]).  Therefore, there were four sets of samples:  low glucose no insulin without acute 15-min 
insulin treatment (LGNI BAS), low glucose no insulin with acute 15-min insulin treatment 
(LGNI INS), high glucose high insulin without acute 15-min insulin stimulation (HGHI BAS) 
and high glucose high insulin with acute 15-min insulin stimulation (HGHI INS).   Cells were 
then collected, homogenized and processed as described [44-46]. The lysate proteins were 
precleared with NIgG and then followed by a PP2Ac immunoprecipitation. The 
immunoprecipitates were washed three times in 700µL TBS. Once all the TBS solution was 
removed, the immunoprecipitates were boiled in 30µL SDS buffer and transferred to a 0.5mL 
centrifugal filter unit in a collection tube. The samples were then washed three times with 200µL 
8M Urea, followed by three washes with 200µL 40mM ammonium bicarbonate (ABC). In 
solution trypsin digestion was then carried out by adding 50µL trypsin in ABC and incubated 
overnight at 37°C on a shaker. More ABC was added to the sample, and supernatant containing 
tryptic peptides were transferred to a collection tube, and placed in a vacuum centrifuge until the 
peptides were completely dried. The peptides were reconstituted in 0.1% TFA in water and 
purified using a C18 ziptip. UPLC-nanoESI analysis using an Orbitrap Fusion Lumos, as 
previously described [44], was performed. 
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2.2.2 Sample Data Analysis 
 Using the MaxQuant software [47-50], peptide/protein identification and quantification 
were performed. Using label-free quantification (LFQ), peak areas for each protein was obtained 
and only proteins with a minimum of 2 unique peptides and a false discovery rate (FDR) at 0.01 
were considered. In total, 1933 proteins were identified in the 32 samples in addition to the two 
isoforms of PP2Ac, PP2Acα and PP2Acβ. To be considered as a PP2A interaction partner, the 
following criteria needed to be satisfied: i) an enrichment ratio >10 and 1063 out of the 1933 
proteins satisfy this criterion; ii) identified with LFQ peak area in more than half of the PP2Ac IP 
(i.e. >16 out of 32 samples used), and 202 out of the 1063 proteins satisfy this criterion, and were 
classified as PP2Ac interaction partner. The enrichment ratio was calculated as follows: 
First, peak area for a protein identified in a sample was normalized against the sum of the 
peak areas for all the proteins identified in that sample to obtain a normalized ratio for the 
individual protein, Norm: i. 
:  =
	

∑ 	



 
Then, the average of normalized ratio for each protein in the PP2Ac IP, Average_Norm: 
i_PP2Ac, as well as the average of normalized ratio for the same protein in the NIgG IP, 
Average_Norm: i_NIgG, were obtained. Finally, Average_Norm: i_PP2Ac was divided by 
Average_Norm: i_NIgG, which gives the enrichment ratio for each protein. 
ℎ :  =
Average_Norm: i_PP2Ac
Average_Norm: i_NIgG
 
 Since NIgG was employed as a negative control, proteins exclusively detected in the 
PP2Ac immunoprecipitates were classified as PP2Ac interaction partners. However, this would 
lead to false negatives because the high sensitivity of our approach would identify a trace amount 
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of a protein non-specifically absorbed on the NIgG beads. However, if this protein is a true 
PP2Ac interaction partner, higher peak area will be assigned to this protein in the PP2Ac sample 
than in the NIgG sample.   
 To determine the relative quantities of PP2Ac interaction partners in the samples, the 
peak area for each protein identified in a specific sample was normalized against the peak area 
for PP2Ac identified in the same sample, Norm: j. 
: ' =
	(
	_2	
 
 The normalization strategy is widely used in proteomics studies involving protein-protein 
interactions [49]. The normalized peak area for each PP2Ac interaction partner, Norm: j, was 
compared among the 4 sets of samples to assess the effects of acute insulin stimulation and /or 
chronicle hyperinsulinemia and hyperglycemia on protein-protein interactions involving PP2Ac. 
 
2.2.3 Statistical Analysis 
 Although a large number of proteins were assigned in at least one of the 32 samples that 
were studied, a number of filters were applied to narrow down the total number of proteins that 
were used to compare the effects of acute insulin stimulation and /or chronicle hyperinsulinemia 
and hyperglycemia among the 4 sets of samples (Figure 4). Statistical calculations were 
performed using the paired t-test and changes were considered significant at p<0.05. 
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CHAPTER 3: RESULTS 
 Clinical characteristics of the eight glucose tolerant lean control participants are listed in 
Table 1. The participants’ average BMI is below 25kg/m2, HbA1c below 5.7 %, fasting plasma 
glucose below 100 mg/dl, 2h OGTT below 100 mg/dl, indicating there are indeed lean healthy 
non-diabetic controls.  In addition, the mean M-value is at 11.0 mg/kg·min, suggesting they are 
insulin sensitive. 
 
3.1 PP2Ac interaction partners in primary skeletal muscle cells from glucose 
tolerant lean human participants 
 PP2Acα and PP2Acβ were detected in PP2Ac immunoprecipitates from all 32 samples, 
but were not detected in all the NIgG immunoprecipitates. In total, 202 proteins met the criteria 
for classification as PP2Ac interaction partners (Figure 4 and Table 2).  
 Among the 202 interaction partners, 18 proteins were previously reported as PP2Ac 
interaction partners in islet beta cells. The known interaction partners include ACP1, CCDC6, 
DLST, GMPPB, IGBP1, NAMPT, PCBP2, PCBP3, PDHX, PPP2R1A, PPP2R2A, PPP4C, 
PPP4R2, PSMA6, SSBP1, TUBB6, VPS25 and VTA1. 
 DAVID pathway analysis on the 202 interaction partners and PP2Ac showed a number of 
pathways significantly enriched when compared to the whole genome background, such as 
pyruvate metabolism, cytoskeleton organization and FGF signaling pathway (Figure 5 and Table 
3). 
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3.2 Nineteen interaction partners of PP2Ac with a significant difference 
among 4 treatment groups. 
 A total of 19 interaction partners showed a significant change in PP2Ac interaction 
among the 4 sets of samples (Table 4 and Figure 6). Under basal conditions (i.e., without acute 
15-minute insulin stimulation), 6 proteins showed a significant change in PP2Ac interaction 
between the low glucose no insulin and chronicle hyperinsulinemia and hyperglycemia 
conditions (LGNI BAS vs HGHI BAS, p<0.05, Table 4 and Figure 6).  Among these 19 partners, 
2 proteins showed significant difference in PP2Ac interaction in LGNI condition in response to 
insulin stimulation (LGNI BAS vs LGNI INS, p<0.05, Table 4 and Figure 6). In HGHI 
conditions, 4 proteins showed significant difference in PP2Ac interaction in response to insulin 
stimulation (HGHI Bas vs HGHI INS, p<0.05, Table 4 and Figure 6). Upon acute insulin 
stimulation, 11 proteins showed significant difference in PP2Ac interaction in HGHI condition 
when compared to the LGNI condition (LGNI INS vs HGHI INS, p<0.05, Table 4 and Figure 6). 
 
 
  
  
15
CHAPTER 4: DISCUSSION 
4.1 PP2Ac interaction partners in primary skeletal muscle cells from glucose 
tolerant lean human participants 
 We have identified 202 PP2Ac interaction partners in the primary skeletal muscle cells of 
8 glucose tolerant lean participants, using a proteomics approach developed in our laboratory [44]. 
Among them, 18 proteins are known PP2Ac interaction partners in islet beta cells recently 
reported by our group (Table 2). 
 From these 18 PP2Ac interaction partners, PPP2R1A and PPP2R2A are A subunit alpha 
isoform and B” subunit alpha isoform of the PP2A complex, respectively.  DLST, 
dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex), is a part of 
the TCA cycle and is responsible for catalyzing the overall conversion of 2-oxoglutarate to 
succinyl-CoA and CO2 [50]. PDHX, pyruvate dehydrogenase protein X component, is a part of 
the PDH complex which provides the primary link between glycolysis and the TCA cycle by 
catalyzing the irreversible conversion of pyruvate into acetyl-CoA [51]. GMPPB, GDP-mannose 
pyrophosphorylase B, is an enzyme that catalyzes the reaction which converts mannose-1-
phophatase and GTP to GDP-mannose [52]. GDP-mannose is necessary for some glycosylation 
pathways to occur. Glycosylation is a post translational modification of proteins that is important 
for proper protein folding [53]. IGBP1, immunoglobulin (CD79A) binding protein 1 and also 
known as alpha4, is involved in the regulation of the catalytic activity of PP2A by protecting its 
partially folded catalytic subunits from degradative polyubiquitination [54, 55]. VPS25, vacuolar 
protein-sorting-associated protein 25, is a protein that is part of the endosomal sorting complex 
required for transporting II (ESCRT-II), which functions in the sorting of ubiquitinated 
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membrane proteins during endocytosis [56]. VTA1, vacuolar protein sorting-associated protein 
VTA1 homolog, is a protein in the ESCRT-IV complex that works in trafficking multivesicular 
bodies [57, 58]. PSMA6, proteasome subunit alpha type-6, is a component of the 20S core 
proteasome complex, which is involved in the proteolytic degradation of most intracellular 
proteins [59]. NAMPT, nicotinamide phosphoribosyltransferase, belongs to the nicotinic acid 
phosphoribosyl transferase (NAPRTase) family and is involved in many biological processes, 
including metabolism, stress response and aging [60]. This protein catalyzes the condensation of 
nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide (an 
intermediate in the biosynthesis of NAD) [61]. SSBP1, single-stranded DNA-binding protein, is a 
protein that is involved in mitochondrial biogenesis and a decrease in mitochondrial function can 
lead to the aging, neurodegeneration and type 2 diabetes [62-64]. TUBB6, tubulin beta-6 chain, is a 
constituent of microtubules, which helps to control insulin secretion and a disturbance in this 
control can lead to beta cell dysfunction and type 2 diabetes [65]. PPP4C, serine/threonine-protein 
phosphatase 4 catalytic subunit, is shown to play a role in microtubule organization at 
centrosomes and PPP4R2, a regulatory subunit of PPP4C, helps regulate the activity of PPP4C 
[66]. PCBP2 and PCBP3, poly(rC)-binding protein 2 and poly(rC)-binding protein 3 respectively, 
are major poly(rC)-binding proteins that negatively regulates cellular antiviral responses 
mediated by the mitochondrial antiviral signaling pathway (MAVS) [67]. In connection to 
diabetes, studies have shown an association between viral infections, like hepatitis C, with 
diabetes [68].  
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4.2 Nineteen interaction partners of PP2Ac with a significant difference 
among 4 treatment groups. 
 Under basal conditions, 6 proteins showed a significant fold change in PP2Ac interaction 
among the low glucose no insulin and high glucose high insulin conditions (LGNI BAS vs HGHI 
BAS, p<0.05, Table 4 and Figure 6).  Of these 6 proteins, 5 of them (ASTML, ESD, GLRX3, 
HINT1 and QKI) showed increased association while only GPX1 showed decreased association.  
QKI, protein quaking, is an RNA-binding protein that plays a central role in myelination, the 
formation of myelin sheath around a nerve fiber [69]. Abnormalities in myelin formation can lead 
to diabetic peripheral neuropathy [70]. GLRX3, glutaredoxin-3, is a part of the glutaredoxin 
family and binds to and modulates the function of PKC-theta [71]. PKC theta has been shown to 
induce insulin-mediated tightening of the muscles by inhibiting Akt [72]. GPX1, glutathione 
peroxidase 1, protects cells against oxidative damage and has been shown to be upregulated by 
IGF-1 in vascular endothelial cells [73]. ROS level elevation in diabetes may be due to decrease in 
destruction or increase in the production by glutathione peroxidase antioxidant [74]. HINT1 
(histidine triad nucleotide-binding protein 1), a tumor suppressor gene, inhibits the Wnt/β-
catenin pathway [75] and has been shown to interact with IRS1, insulin receptor substrate 1, along 
with PP2Ac in human skeletal muscle [44]. ESD, S-formylglutathione hydrolase, is an enzyme 
that is involved in the detoxification of formaldehyde [76]. 
 Among these 19 partners, 2 proteins showed significant difference in PP2Ac interaction 
in the low glucose no insulin condition in response to insulin stimulation (LGNI BAS vs LGNI 
INS, p<0.05, Table 4). Both CCDC6 and GLRX3 showed increased association with PP2Ac. 
CCDC6 (coiled-coil domain containing 6), a tumor suppressor gene, is involved in apoptosis and 
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DNA damage response [77]. GLRX3, as mentioned previously, is a part of the glutaredoxin 
family and binds to and modulates the function of PKC-theta [71]. 
 In hyperinsulinemia and hyperglycemia conditions, 4 proteins showed significant 
difference in PP2Ac interaction in response to insulin stimulation (HGHI BAS vs HGHI INS, 
p<0.05, Table 4).  ACP1 and HINT1 both showed decreased association with PP2Ac, while 
CYCS and HSPB6 showed increased association with PP2Ac. HSPB6, heat shock protein beta-6, 
plays a role in regulating muscle function such as smooth muscle vasorelaxation and cardiac 
myocyte contractility [78]. CYCS (cytochrome c), a small heme protein, is known to be involved 
in electron transport chain in the mitochondria and involved in the initiation of apoptosis [79]. 
ACP1, low molecular weight phosphotyrosine protein phosphatase, is an acid phosphatase and 
protein tyrosine phosphatase that plays an important role in the control of insulin receptor 
activity [80]. 
 Upon insulin stimulation, 11 proteins showed significant difference in PP2Ac interaction 
in the hyperinsulinemia and hyperglycemia condition when compared to the LGNI condition 
(LGNI INS vs HGHI INS, p<0.05, Table 4). All 11 proteins (TAK1L, DCAMKL1, ESD, GSS, 
HINT1, IGBP1, SEP11, TPPP3, UCK2, GRIPAP1 and S100A13) showed decreased association 
with PP2Ac. IGBP1, as previously mentioned, binds to PP2Ac to stabilize it [54, 55]. DCAMKL1, 
doublecortin Like Kinase 1, is a kinase involved in the Ca2+ signaling pathway controlling 
neuronal migration [81]. GRIPAP1, GRIP1-associated protein 1, functions as a JNK pathway 
scaffold protein, binding both JNK and the upstream kinase MEKK1 in neurons [82]. SEP11, 
septin-11, is a filament-forming cytoskeletal GTPase that plays a role in cytokinesis and vesicle 
trafficking [83]. TPPP3, tubulin polymerization-promoting protein family member 3, has 
microtubule binding activity and plays a role in cell proliferation and mitosis [84].  UCK2, 
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uridine-cytidine kinase 2, catalyzes uridine and cytidine phosphorylation to uridine 
monophosphate (UMP) and cytidine monophosphate (CMP), respectively [85]. GSS, Glutathione 
synthetase, is involved in the glutathione biosynthesis pathway [86]. Glutathione synthesis has 
been seen to be diminished in diabetic patients [87]. 
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CHAPTER 5: SUMMARY 
 In the present work, PP2Ac was found to interact either directly or indirectly with 202 
interaction partners in primary human skeletal muscle cells and 19 PP2Ac interaction partners 
were identified to show a significant change among the four treatment conditions (LGNI BAS, 
LGNI INS, HGHI BAS and HGHI INS). Validating the important partners that may affect the 
insulin signaling pathway (directly or indirectly) would be the next step. In addition, comparing 
PP2Ac interaction partners in primary human skeletal muscle cells with/out HGHI treatment 
with those from obese and type 2 diabetic participants will help to uncover the differences in the 
PP2Ac interaction partners among the 3 groups. With this information, we may have a better 
understanding of the role of PP2Ac in the insulin signaling pathway in primary human skeletal 
muscle cells and ultimately better knowledge on the development of insulin resistance and type 2 
diabetes.  
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FIGURES 
 
 
 
Figure 1. Insulin signaling pathway showing some of the signaling molecules involved and 
the effects seen [10].    
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Figure 2. Structure of the heterotrimeric PP2A holoenzyme [88].  
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Figure 3. Clinical and proteomic data acquisition and analysis 
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Figure 4. Proteomic data analysis 
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Figure 5. Significantly enriched pathways for the 202 interaction partners and PP2Ac in 
primary human skeletal muscle cells 
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Figure 6. Interaction partners that showed significant difference among 4 treatment 
groups. Mean of the normalized peak area for eachPP2Ac interaction partner in the LGNI 
BAS samples was set to 1.00, and all the fold changes were relative to LGNI BAS.  *: 
p<0.05 vs. LGNI BAS, #: P<0.05 vs. HGHI BAS, and &: p<0,05 vs. LGLI INS 
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TABLES 
Table 1. Clinical characteristics for 8 lean participants in this study. Results were shown as 
mean ± SEM. [Cutoff values] 
  
Gender (M/F) (4/4) 
Body Mass Index (kg/m
2
) 21.3 ± 2.2 [25] 
HbA1C (%) 5.4 ± 0.2 [5.7] 
Fasting Plasma Glucose (mg/dl) 84.9 ± 5.6 [100]  
2h OGTT (mg/dl) 106.6 ± 15.1 [140] 
M-value (mg/kg·min) 11.0 ± 3.1 [5] 
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Table 2. The 202 protein groups that met the 2 criteria (See Methods for details) for 
classification as PP2Ac interaction partners in primary human skeletal muscle cells. (* 
indicates previously identified PP2A partners in INS-1 832/13 beta-cells).  
Gene name Protein name 
PPP2R1A* Serine/threonine-protein phosphatase 2A 65kDa regulatory subunit A 
alpha isoform 
PPP2R2A* Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B 
alpha isoform 
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit 
delta isoform 
PPP2R5E Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit 
epsilon isoform 
A2M Alpha-2-Macroglobulin 
ACAT1 Acetyl-CoA Acetyltransferase 1, mitochondrial 
ACP1* Low molecular weight phosphotyrosine protein phosphatase; Acid 
phosphatase 1, soluble 
ACTA1 Actin, alpha skeletal muscle 
ACTB, ACTG1 Actin, cytoplasmic 1; Actin, cytoplasmic 1, N-terminally processed; 
Actin, cytoplasmic 2; Actin, cytoplasmic 2, N-terminally processed 
ACYP2 Acylphosphatase-2;Acylphosphatase 
ADA Adenosine deaminase 
AKR1B1 Aldose reductase 
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AKR1C1, 
AKR1C2, 
AKR1C3, AKR1C4 
Aldo-keto reductase family 1 member C1;Aldo-keto reductase family 1 
member C2;Aldo-keto reductase family 1 member C3;Aldo-keto 
reductase family 1 member C4 
ALDH1A1 Retinal dehydrogenase 1 
ALDH7A1 Alpha-aminoadipic semialdehyde dehydrogenase 
ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase 
AP2M1 AP-2 complex subunit mu 
APOBEC2 Probable C->U-editing enzyme APOBEC-2 
ASAH1 Acid ceramidase; Acid ceramidase subunit alpha; Acid ceramidase 
subunit beta 
ASMTL N-acetylserotonin O-methyltransferase-like protein 
ATP5D ATP synthase subunit delta, mitochondrial 
ATXN2L Ataxin-2-like protein 
BAP18, C17ORF49 Chromatin complexes subunit BAP18 
BCAS3 Breast carcinoma-amplified sequence 3 
BCAT1 Branched-chain-amino-acid aminotransferase, cytosolic 
BOD1 Biorientation of chromosomes in cell division protein 1 
BOLA2, BOLA2B BolA-like protein 2 
BROX, C1ORF58 BRO1 domain-containing protein BROX 
C1QTNF5 Complement C1q tumor necrosis factor-related protein 5 
C21ORF7, TAK1L TAK1-like protein 
CAPRIN1 Caprin-1 
CAT Catalase 
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CCDC6* Coiled-coil domain containing 6 
CDV3 Protein CDV3 homolog 
CHCHD3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, 
mitochondrial 
CHMP1A Charged multivesicular body protein 1a 
CIAPIN1 Anamorsin 
CIP29, SARNP SAP domain-containing ribonucleoprotein 
CKB Creatine kinase B-type 
CLCC1 Chloride channel CLIC-like protein 1 
COMT Catechol O-methyltransferase 
COPS8 COP9 signalosome subunit 8 
CORO1B Coronin-1B 
CPPED1 Calcineurin-like phosphoesterase domain-containing protein 1 
CRYZ Quinone oxidoreductase 
CTPS CTP synthase 1 
CTSA Lysosomal protective protein; Lysosomal protective protein 32 kDa 
chain; Lysosomal protective protein 20 kDa chain 
CTTN Src substrate cortactin 
CYCS Cytochrome c 
DBI Acyl-CoA-binding protein 
DCAMKL1 Doublecortin Like Kinase 1 
DCTN3 Dynactin subunit 3 
DDB1 DNA damage-binding protein 1 
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DDX19B ATP-dependent RNA helicase DDX19B 
DLST* Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-
glutarate complex) 
DR1 Protein Dr1 
DYSF Dysferlin 
EIF2B1 Translation initiation factor eIF-2B subunit alpha 
EIF4A3 Eukaryotic initiation factor 4A-III 
EIF4H Eukaryotic translation initiation factor 4H 
ESD S-formylglutathione hydrolase 
ETF1 Eukaryotic peptide chain release factor subunit 1 
EZR Ezrin 
FABP3 Fatty acid-binding protein, heart 
FARSB Phenylalanine--tRNA ligase beta subunit 
FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A; Peptidyl-prolyl cis-trans 
isomerase 
FKBP9 Peptidyl-prolyl cis-trans isomerase FKBP9 
FUBP1 Far upstream element-binding protein 1 
GLRX3 Glutaredoxin-3 
GMPPB* GDP-mannose pyrophosphorylase B 
GORASP2 Golgi reassembly-stacking protein 2 
GPI Glucose-6-phosphate isomerase 
GPX1 Glutathione peroxidase 1 
GRIPAP1 GRIP1-associated protein 1 
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GSPT1 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 
GSS Glutathione synthetase 
H2AFJ, H2AFV, 
H2AFX, H2AFZ, 
HIST1H2AA, 
HIST1H2AB, 
HIST1H2AC, 
HIST1H2AD, 
HIST1H2AG, 
HIST1H2AH, 
HIST1H2AJ, 
HIST2H2AA3, 
HIST2H2AB, 
HIST2H2AC, 
HIST3H2A 
Histone H2A.x; Histone H2A type 1-A; Histone H2A type 1-B/E; 
Histone H2A type 1; Histone H2A type 1-D; Histone H2A type 2-A; 
Histone H2A type 3; Histone H2A type 1-C; Histone H2A type 2-B; 
Histone H2A type 2-C; Histone H2A.J; Histone H2A type 1-H; Histone 
H2A type 1-J; Histone H2A.Z; Histone H2A.V; Histone H2A 
HINT1 Histidine triad nucleotide-binding protein 1 
HIST1H1E Histone H1.4 
HIST1H4A Histone H4 
HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
HN1 Hematological and neurological expressed 1 protein 
HSPA4L Heat shock 70 kDa protein 4L 
HSPB6 Heat shock protein beta-6 
HSPE1 10 kDa heat shock protein, mitochondrial 
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HTRA1 Serine protease HTRA1 
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic 
IGBP1* Immunoglobulin (CD79A) binding protein 1 
IMPA1 Inositol monophosphatase 1 
IST1 IST1 homolog 
ITGA5 Integrin alpha-5; Integrin alpha-5 heavy chain; Integrin alpha-5 light 
chain 
IVD Isovaleryl-CoA dehydrogenase, mitochondrial 
KHSRP Far upstream element-binding protein 2 
LSS Lanosterol synthase 
LYPLA1 Acyl-protein thioesterase 1 
MAN2B1 Lysosomal alpha-mannosidase; Lysosomal alpha-mannosidase A 
peptide; Lysosomal alpha-mannosidase B peptide; Lysosomal alpha-
mannosidase C peptide; Lysosomal alpha-mannosidase D peptide; 
Lysosomal alpha-mannosidase E peptide 
MATR3 Matrin-3 
METTL11A Alpha N-terminal protein methyltransferase 1A 
MPI Mannose-6-phosphate isomerase 
MVD Diphosphomevalonate decarboxylase 
MYOM3 Myomesin-3 
NAMPT* Nicotinamide phosphoribosyltransferase 
NASP Nuclear autoantigenic sperm protein 
NIT2 Omega-amidase NIT2 
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NME1, NME2, 
NME2P1 
Nucleoside diphosphate kinase; Nucleoside diphosphate kinase B; 
Putative nucleoside diphosphate kinase 
NSFL1C NSFL1 cofactor p47 
NUDCD2 NudC domain-containing protein 2 
NUDT5 ADP-sugar pyrophosphatase 
OSBPL9 Oxysterol-binding protein; Oxysterol-binding protein-related protein 9 
OXCT1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial 
PCBP2*, PCBP3* Poly(rC)-binding protein 2; Poly(rC)-binding protein 3 
PCMT1 Protein-L-isoaspartate O-methyltransferase; Protein-L-isoaspartate(D-
aspartate) O-methyltransferase 
PDCD5 Programmed cell death protein 5 
PDHX* Pyruvate dehydrogenase protein X component, mitochondrial 
PDLIM4 PDZ and LIM domain protein 4 
PEBP1 Phosphatidylethanolamine-binding protein 1; Hippocampal cholinergic 
neurostimulating peptide 
PEPD Xaa-Pro dipeptidase 
PFDN1 Prefoldin subunit 1 
PFDN2 Prefoldin subunit 2 
PFN1 Profilin-1 
PGM3 Phosphoacetylglucosamine mutase 
PHB Prohibitin 
PMPCA Mitochondrial-processing peptidase subunit alpha 
POLR2H DNA-directed RNA polymerases I, II, and III subunit RPABC3 
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PPP4C* Serine/threonine-protein phosphatase 4 catalytic subunit; 
Serine/threonine-protein phosphatase 
PPP4R1 Serine/threonine-protein phosphatase 4 regulatory subunit 1 
PPP4R2* Serine/threonine-protein phosphatase 4 regulatory subunit 2 
PRDX2 Peroxiredoxin-2 
PRKACA, 
PRKACB 
cAMP-dependent protein kinase catalytic subunit beta; cAMP-
dependent protein kinase catalytic subunit alpha 
PROSC Proline synthase co-transcribed bacterial homolog protein 
PSMA6* Proteasome subunit alpha type; Proteasome subunit alpha type-6 
PSMB4 Proteasome subunit beta type-4 
PTER Phosphotriesterase-related protein 
PTK2 Focal adhesion kinase 1 
PTMS Parathymosin 
QKI Protein quaking 
QTRT1 Queuine tRNA-ribosyltransferase 
RAB11A, RAB11B Ras-related protein Rab-11B;Ras-related protein Rab-11A 
RABEP2 Rab GTPase-binding effector protein 2 
RAD23A UV excision repair protein RAD23 homolog A 
RAPH1 Ras-associated and pleckstrin homology domains-containing protein 1 
RPS21 40S ribosomal protein S21 
RPSA, RPSAP58 40S ribosomal protein SA 
RSU1 Ras suppressor protein 1 
RTCD1 RNA 3-terminal phosphate cyclase 
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RTN1 Reticulon-1 
S100A13 Protein S100-A13 
S100A4 Protein S100-A4 
S100Z Protein S100-Z 
SAR1A GTP-binding protein SAR1a 
SARS Serine--tRNA ligase, cytoplasmic 
SBDS Ribosome maturation protein SBDS 
SCRN1 Secernin-1 
SEP11 Septin-11 
SERPINB1 Leukocyte elastase inhibitor 
SERPINB6 Serpin B6 
SERPINC1 Antithrombin-III 
SERPINE1 Plasminogen activator inhibitor 1 
SET  Protein SET 
SETD7 Histone-lysine N-methyltransferase SETD7 
SF3A1 Splicing factor 3A subunit 1 
SFPQ Splicing factor, proline- and glutamine-rich 
SLC9A3R1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 
SNX1 Sorting nexin-1 
SNX12 Sorting nexin-12 
SNX17 Sorting nexin-17 
SOD1 Superoxide dismutase [Cu-Zn] 
SORD Sorbitol dehydrogenase 
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SPAG7 Sperm-associated antigen 7 
SRP9 Signal recognition particle 9 kDa protein 
SSBP1* Single-stranded DNA-binding protein, mitochondrial 
ST13, ST13P5 Hsc70-interacting protein; Putative protein FAM10A5 
STMN1 Stathmin 
SWAP70 Switch-associated protein 70 
SYNPO2L Synaptopodin 2-like protein 
TBCA Tubulin-specific chaperone A 
TCEB2 Transcription elongation factor B polypeptide 2 
TFG Protein TFG 
THBS1 Thrombospondin-1 
TMEM189, 
UBE2V1 
Ubiquitin-conjugating enzyme E2 variant 1 
TMF1 TATA element modulatory factor 
TMSB10 Thymosin beta-10 
TMSB4X Thymosin beta-4; Hematopoietic system regulatory peptide 
TPM2 Tropomyosin beta chain 
TPP1 Tripeptidyl-peptidase 1 
TPPPP3 Tubulin polymerization-promoting protein family member 3 
TSG101 Tumor susceptibility gene 101 protein 
TTC17 Tetratricopeptide repeat protein 17 
TTC9 Tetratricopeptide repeat protein 9A 
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TUBA1A, 
TUBA1B 
Tubulin alpha-1B chain; Tubulin alpha-1A chain 
TUBB6* Tubulin beta-6 chain 
TXNDC5 Thioredoxin domain-containing protein 5 
TXNL1 Thioredoxin-like protein 1 
TXNRD1 Thioredoxin reductase 1, cytoplasmic 
UAP1 UDP-N-acetylhexosamine pyrophosphorylase; UDP-N-
acetylgalactosamine pyrophosphorylase; UDP-N-acetylglucosamine 
pyrophosphorylase 
UBE2D3 Ubiquitin-conjugating enzyme E2 D3 
UBL4A Ubiquitin-like protein 4A 
UCK2 Uridine-cytidine kinase 2 
VPS25* Vacuolar protein-sorting-associated protein 25 
VTA1* Vacuolar protein sorting-associated protein VTA1 homolog 
VWA5A von Willebrand factor A domain-containing protein 5A 
ZNF157 Zinc finger protein 157 
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Table 3. Significantly enriched pathways for the PP2Ac interaction partners identified in 
this study revealed by DAVID pathway analysis 
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Carboxylic acid 
metabolic process 
2.83 
BCAT1, DLST, PEPD, CTPS, 
SARS, LYPLA1, CKB, GSS, 
AKR1C3, AKR1C2, GPI, FARSB, 
FABP3, QKI, IDH1, PDHX, 
AKR1C1, ALDH9A1 
18 
Protein 
biosynthesis 
2.82 
RPSA, EIF4A3, GSPT1, EIF4H, 
SARS, RPSAP58, FARSB, ETF1, 
RPS21, EIF2B1 
9 
Protein folding 2.63 
ST13, PFDN2, FKBP9, PFDN1, 
TBCA, HSPA4L, TTC9, HSPE1, 
FKBP1A 
9 
Protein 
metabolism 
2.37 
ACTB, FKBP9, RPSA, ETF1, 
EIF2B1, PFDN2, PFDN1, TBCA, 
RPSAP58, EIF4H, TUBB6, 
TUBA1A, RPS21, TUBA1B 
13 
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FGF signaling 
pathway 
2.31 
PPP2R1A, PPP4R1, PPP2CA, 
PPP2R5D, PPP2CB, PEBP1, 
PPP2R5E, PPP2R2A 
8 
Pyruvate 
metabolism 
1.97 
ALDH7A1, AKR1B1, ACYP2, 
ACAT1, ALDH9A1 
5 
Monosaccharide 
biosynthetic 
process 
1.90 
PGM3, GPI, UAP1, SORD 
4 
Signaling by Wnt 1.87 
PSMB4, PPP2R1A, PSMA6, 
PPP2CA, PPP2R5D, PPP2CB 
6 
Amino sugar and 
nucleotide sugar 
metabolism 
1.83 
GMPPB, PGM3, GPI, UAP1, MPI 
5 
Alcohol 
biosynthetic 
process 
1.69 
PGM3, GPI, UAP1, SORD 
 4 
Cytoskeleton 
organization 
1.53 
ACTG1, PFN1, TPPP3, PTK2, EZR, 
ACTA1, TMSB4X, TMSB10, 
STMN1, SOD1, PPP4C, TUBA1B 
12 
  
49
Regulation of 
intracellular 
protein kinase 
cascade 
1.33 
PPP2R1A, GPX1, PPP2CA, 
UBE2V1, TFG, PEBP1, FKBP1A, 
CAT, TMEM189 
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Table 4. Interaction partners that showed significant difference upon insulin stimulation.  
 
Gene Name Protein Name 
Fold 
change 
LGNI 
BAS 
Fold 
change 
LGNI INS 
Fold change 
HGHI BAS 
Fold 
change 
HGHI INS 
ACP1 
Low molecular 
weight 
phosphotyrosine 
protein phosphatase 
1.00±0.85 0.44±0.12 1.79±1.59 0.25±0.08# 
ASMTL 
N-acetylserotonin 
O-
methyltransferase-
like protein 
1.00±0.43 2.05±0.54 9.04±8.28* 1.65±0.05 
TAK1L TAK1-like protein 1.00±0.72 0.73±0.28 2.74±2.41 0.22±0.1& 
CCDC6 
Coiled-coil domain-
containing protein 6 
1.00±0.42 4.03±1.46* 23.95±19.63 1.74±0.49 
CYCS Cytochrome c 1.00±0.99 0.05±0.03 0.03±0.02 0.07±0.05# 
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DCAMKL1 
Serine/threonine-
protein kinase 
DCLK1 
1.00±0.54 2.09±1.01 1.40±0.97 0.64±0.23& 
ESD 
S-formylglutathione 
hydrolase 
1.00±0.75 1.33±0.53 2.43±1.69* 0.23±0.06& 
GLRX3 Glutaredoxin-3 1.00±0.21 2.87±0.96* 16.89±15.68* 1.29±0.36 
GPX1 
Glutathione 
peroxidase 1 
1.00±0.99 0.02±0.01 0.10±0.10* 0.01±0 
GRIPAP1 
GRIP1-associated 
protein 1 
1.00±0.76 0.42±0.1 2.23±1.87 0.24±0.07& 
GSS 
Glutathione 
synthetase 
1.00±0.94 0.67±0.48 1.17±0.92 0.49±0.45& 
HINT1 
Histidine triad 
nucleotide-binding 
protein 1 
1.00±0.72 2.83±1.08 3.31±2.45* 0.68±0.40#,& 
HSPB6 
Heat shock protein 
beta-6 
1.00±0.33 3.5±1.76 7.37±3.15 4.02±2.29# 
IGBP1 
Immunoglobulin-
binding protein 1 
1.00±0.32 1.67±0.63 3.58±2.48 0.76±0.23& 
QKI Protein quaking 1.00±0.88 0.45±0.17 3.8±3.35* 0.68±0.32 
S100A13 Protein S100-A13 1.00±0.51 0.43±0.07 0.98±0.76 0.21±0.05& 
SEP11 Septin-11 1.00±0.54 0.82±0.34 1.93±1.18 0.42±0.19& 
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TPPP3 
Tubulin 
polymerization-
promoting protein 
family member 3 
1.00±0.88 0.59±0.27 1.09±0.91 0.14±0.07& 
UCK2 
Uridine-cytidine 
kinase 2 
1.00±0.59 0.4±0.11 1.5±1.34 0.19±0.03& 
  
Data are given as fold changes (means ± SEM).  Peak area for each protein identified in a 
specific sample was normalized against the peak area for PP2Ac identified in the same sample 
(See Methods). The normalized peak area for each PP2Ac interaction partner was compared 
among the 4 sets of samples to assess effects of acute insulin stimulation or effects of 
hyperinsulinemia hyperglycemia on protein-protein interactions involving PP2Ac. Mean of the 
normalized peak area for eachPP2Ac interaction partner in the LGNI BAS samples was set to 
1.00, and all the fold changes were relative to LGNI BAS.  *: p<0.05 vs. LGNI BAS, #: P<0.05 
vs. HGHI BAS, and &: p<0,05 vs. LGLI INS. 
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ABSTRACT 
PROTEIN PHOSPHATASE 2A: FUNCTION AND REGULATION IN 
INSULIN RESISTANT HUMAN SKELETAL MUSCLE MYOTUBES 
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Degree: Master of Science 
Protein Phosphatase 2A (PP2A), a major serine/threonine phosphatase involved in 
insulin signaling pathway, plays a critical role in the development of insulin resistance 
and type 2 diabetes (T2D), which is characterized with hyperinsulinemic hyperglycemic 
condition. Moreover, majority of the glucose disposal takes place in the skeletal muscle 
which is also the main tissue responsible for insulin resistance. The catalytic subunit of 
PP2A (PP2Ac) can interact with multiple regulatory subunits and other regulatory 
proteins as well as substrates. These interactions are important for maintain normal PP2A 
function and subsequent cell signaling.   We hypothesized that hyperinsulinemic 
hyperglycemic condition and insulin stimulation would result in differentially changed 
protein-protein interactions involving PP2Ac in primary human skeletal muscle cells 
derived from lean healthy participants.  
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Using UPLC-nanoESI-MS/MS, 202 PP2Ac interaction partners were identified in 
primary human skeletal muscle cells from 8 lean heathy participants. Out of which 18 
partners were previously identified in the islet beta cells by our group. In addition, 19 
interaction partners of PP2Ac showed a significant difference among 4 treatment groups: 
low glucose no insulin without acute 15-min insulin treatment (LGNI BAS), low glucose 
no insulin with acute 15-min insulin treatment (LGNI INS), high glucose high insulin 
without acute 15-min insulin stimulation (HGHI BAS) and high glucose high insulin with 
acute 15-min insulin stimulation (HGHI INS).   Under basal conditions (i.e., without 
acute 15-minute insulin stimulation), 6 proteins showed a significant change in PP2Ac 
interaction between the low glucose no insulin and chronicle hyperinsulinemia and 
hyperglycemia conditions (LGNI BAS vs HGHI BAS, p<0.05).  In addition, 2 proteins 
showed significant difference in PP2Ac interaction in LGNI condition in response to 
insulin stimulation (LGNI BAS vs LGNI INS, p<0.05). In HGHI conditions, 4 proteins 
showed significant difference in PP2Ac interaction in response to insulin stimulation 
(HGHI Bas vs HGHI INS, p<0.05). Upon acute insulin stimulation, 11 proteins showed 
significant difference in PP2Ac interaction in HGHI condition when compared to the 
LGNI condition (LGNI INS vs HGHI INS, p<0.05). These differential changes of PP2Ac 
interaction partners among the 4 treatments provide new information regarding PP2A in 
primary human skeletal muscle cells under hyperinsulinemic hyperglycemic conditions. 
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